Home
·
Contributors
·
Maria Dranishnikova
Maria Dranishnikova

Maria Dranishnikova

Oninvest reporter

Writes about:

Articles: 1006

Regulators have agreed to review Biohaven’s application for approval of an experimental treatment for a rare disease that causes a gradual loss of muscle control / Photo: Facebook / Biohaven
Small Caps·

Biohaven soars 25% as drug moves closer to approval. Is there more upside?

Lycia shares will trade on the Nasdaq under the ticker LYCA / Photo: X / Lycia Therapeutics
Small Caps·

Lycia IPO: Food allergy biotech cofounded by Nobel laureate debuts on the Nasdaq

Archer Aviation, valued at around $3 billion, is developing vertical takeoff and landing air taxis / Photo: www.archer.com
Small Caps·

Motley Fool: Six next-generation tech stocks not to forget amid the Anthropic IPO

Ken Griffin’s Citadel manages $77 billion, according to company data as of October 1 / Photo: Erlin Diah / Shutterstock.com
Small Caps·

AI needs power and computing capacity: Three Griffin holdings with up to 400% upside

Braze helps marketers to deepen customer relationships, responding to customer behavior in real time to coordinate personalized experiences across channels, the Journal notes / Photo: Instagram / Braze
Small Caps·

Software maker Braze soars 50% as Salesforce agrees to buy it for $5.66 bln

Disc stock jumped 39% after a successful trial for its drug bitopertin, its best day since late 2022 / Photo: www.discmedicine.com
Small Caps·

Disc Medicine has best day in 4 years as its blood-disorder drug succeeds in trial

Victoria’s Secret is up more than 60% year to date and around 180% over the last 12 months / Photo: Instagram / victoriassecret
Small Caps·

Needham makes case for obesity drugs as long-term catalyst for Victoria’s Secret

Nordic American Tankers, with a market capitalization of $1.67 billion, owns and operates a fleet of large crude oil tankers / Photo: www.nat.bm
Small Caps·

Strategist picks three small caps bucking the Russell 2000 slump

The company is developing RNAi-based drugs to treat thromboembolic diseases and Stargardt disease, with its lead product in early-stage trials / Photo: City Therapeutics
Small Caps·

City Therapeutics IPO: Developer of RNAi-based drugs debuts on the Nasdaq